0H7R.L

Abeona Therapeutics Inc. [0H7R.L] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0H7R.L Stock Summary

Earnings have grown 147.52% per last year.

The Moving Average Convergence Divergence (MACD) for 0H7R.L recently turned positive (within last 10 days).

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

Top 10 Correlated ETFs

0H7R.L

Top 10 Correlated Stocks

0H7R.L

In the News

0H7R.L Financial details

Company Rating

Market Cap

216.36M

Income

-54.19M

Revenue

3.5M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 May 2024

P/E

-3.68

Forward P/E

PEG

0.76

P/S

39.92

P/B

6.47

P/C

P/FCF

-3.38

Quick Ratio

6.39

Current Ratio

6.81

Debt / Equity

LT Debt / Equity

EPS (TTM)

-2.59

EPS next Y

EPS next Q

EPS this Y

-49.9%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

35.42%

SMA20

7.89%

SMA50

-9.35%

SMA100

-13.05%

Inst Own

Inst Trans

ROA

-59%

ROE

-201%

ROC

-0.81%

Gross Margin

-597%

Oper. Margin

-1317%

Profit Margin

-1085%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

2.3501-8.8

52W High

-15.63%

52W Low

+237.5%

RSI

72.57

Rel Volume

237.86

Avg Volume

1.01K

Volume

239.53K

Perf Week

37.2%

Perf Month

29.56%

Perf Quarter

6.97%

Perf Half Y

1.2%

Beta

1.479

Volatility

0.54%, 0.48%

Prev Close

34.73%

Price

6.75

Change

12.5%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.01K
Market Capitalization 216.36M
Employee 84
CEO Dr. Vishwas Seshadri M.B.A., Ph.D.
Headquarters New York,NY,US
IPO Date 2018-01-29
Website https://www.abeonatherapeutics.com

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.